编者按：2025年美国临床肿瘤学会（ASCO）年会定于5月30日至6月3日（美国东部时间，ET）在美国芝加哥举办。作为全球规模最大、学术水平最高且最具权威性的临床肿瘤学盛会，ASCO年会汇聚了全球肿瘤学领域的医生、专业人士、患者倡导者、工业界代表以及主流媒体，共同聚焦国际前沿的研究发现与临床试验成果。

 

近日，大会公布了最新口头报告摘要题目等重要信息。《肿瘤瞭望》特将肺癌领域口头及快速口头摘要报告研究标题进行整理，其中，10余项来自中国的重磅研究成果入选，以飨读者。

 

英文标题:Overall survival with neoadjuvant nivolumab(NIVO)+chemotherapy(chemo)in patients with resectable NSCLC in CheckMate 816.

中文标题:CheckMate 816研究中可切除NSCLC患者新辅助纳武利尤单抗（NIVO）+化疗（chemo）的总生存期分析

汇报者:Patrick M.Forde，MD，PhD|Trinity St.James’s Cancer Institute，Trinity College Dublin

 

英文标题:R-ALPS:A randomized，double-blind，placebo-controlled，multicenter phase III clinical trial of TQB2450 with or without anlotinib as maintenance treatment in patients with locally advanced and unresectable(stage III)NSCLC without progression following concurrent or sequential chemoradiotherapy.

中文标题:R-ALPS研究：一项随机、双盲、安慰剂对照、多中心III期临床试验，旨在评估贝莫苏拜单抗（TQB2450）联合或不联合安罗替尼作为维持治疗，在同步或序贯放化疗后未进展的局部晚期不可切除（III期）非小细胞肺癌患者中的疗效

汇报者:陈明教授|中山大学肿瘤防治中心

 

英文标题:CAMPASS:Benmelstobart in combination with anlotinib vs pembrolizumab in the first-line treatment of advanced non-small cell lung cancer(aNSCLC):A randomized，single-blind，multicenter phase 3 study.

中文标题:CAMPASS研究：Benmelstobart联合anlotinib对比帕博利珠单抗一线治疗晚期非小细胞肺癌（aNSCLC）：一项随机、单盲、多中心3期研究

汇报者:韩宝惠教授｜上海市胸科医院

 

英文标题:Savolitinib(Savo)combined with osimertinib(osi)versus chemotherapy(chemo)in EGFR-mutant(EGFRm)and MET-amplification(METamp)advanced NSCLC after disease progression(PD)on EGFR tyrosine kinase inhibitor(TKI):Results from a randomized phase 3 SACHI study.

中文标题:SACHIⅢ期研究：赛沃替尼联合奥希替尼对比化疗用于EGFR突变且MET扩增的晚期NSCLC患者（在EGFR TKI治疗失败后）的随机对照结果

汇报者:陆舜教授｜上海市胸科医院

 

英文标题:Phase I study of iza-bren(BL-B01D1)，an EGFR x HER3 bispecific antibody-drug conjugate(ADC)，in patients with locally advanced or metastatic non-small cell lung cancer(NSCLC)with driver genomic alterations(GA)outside of classic EGFR mutations.

中文标题:BL-B01D1（iza-bren）治疗携带经典EGFR突变以外驱动基因改变的局部晚期或转移性非小细胞肺癌的I期临床研究：一种靶向EGFR×HER3的双特异性ADC的评估

汇报者:杨云鹏教授|中山大学肿瘤防治中心

 

英文标题:Neoadjuvant(neoadj)osimertinib(osi)±chemotherapy(CT)vs CT alone in resectable(R)epidermal growth factor receptor-mutated(EGFRm)NSCLC:NeoADAURA.

中文标题:NeoADAURA：可切除EGFRm NSCLC术前新辅助奥希替尼±化疗vs单纯化疗的对比研究

汇报者:Jamie E.Chaft，MD，FASCO|Thoracic Oncology Service，Memorial Sloan Kettering Cancer Center，New York，NY;Department of Medicine，Weill Cornell Medical College

 

英文标题:Lung cancer diagnosis rates(LCDR)in lung cancer screening(LCS)and incidental pulmonary nodule(IPN)cohorts in the Mississippi Delta.

中文标题:密西西比三角洲地区肺癌筛查与偶然发现肺结节队列中的肺癌诊断率研究

汇报者:Raymond U.Osarogiagbon，MBBS，FACP，FASCO|Baptist Cancer Center，Multidisciplinary Thoracic Oncology Program

英文标题:SWOG/NRG S1914:Randomized phase III trial of induction/consolidation atezolizumab+SBRT versus SBRT alone in high risk，early-stage NSCLC.

中文标题:SWOG/NRG S1914:高危早期NSCLC诱导/巩固期阿替利珠单抗+SBRT对比单纯SBRT的随机Ⅲ期试验

汇报者:Megan Eileen Daly，MD|Department of Radiation Oncology，University of California Davis Comprehensive Cancer Center

英文标题:First-line adagrasib(ADA)with pembrolizumab(PEMBRO)in patients(pts)with advanced/metastatic KRASG12C-mutated non-small cell lung cancer(NSCLC)from the phase 2 portion of the KRYSTAL-7 study.

中文标题:KRYSTAL?7Ⅱ期研究：一线阿达格拉西布联合帕博利珠单抗治疗晚期/转移性KRAS G12C突变非小细胞肺癌（NSCLC）患者KRYSTAL?7Ⅱ期研究：一线阿达格拉西布联合帕博利珠单抗治疗晚期/转移性KRAS G12C突变非小细胞肺癌（NSCLC）患者

汇报者:Pasi A.Jänne，PhD|Department of Medical Oncology，Lowe Center for Thoracic Oncology，Dana-Farber Cancer Institute

 

英文标题:TROPION-Lung02:Datopotamab deruxtecan(Dato-DXd)plus pembrolizumab(pembro)with or without platinum chemotherapy(Pt-CT)as first-line(1L)therapy for advanced non-small cell lung cancer(aNSCLC).

中文标题:TROPION?Lung02：Dato?DXd联合帕博利珠单抗±铂类化疗用于晚期NSCLC一线治疗

汇报者:Benjamin Philip Levy，MD，FASCO|Sidney Kimmel Comprehensive Cancer Center，Johns Hopkins Medicine

 

英文标题:Efficacy of zipalertinib in NSCLC patients with EGFR exon 20 insertion mutations who received prior platinum-based chemotherapy with or without amivantamab.

中文标题:Zipalertinib在接受过含铂化疗±无埃万妥单抗治疗的EGFR外显子20插入突变NSCLC患者中的疗效评估

汇报者:Helena Alexandra Yu，MD|Memorial Sloan Kettering Cancer Center

 

英文标题:SOHO-01:Safety and efficacy of BAY 2927088 in patients with advanced HER2-mutant non-small cell lung cancer(NSCLC)who were pretreated but naïve to HER2-targeted therapy or had not received any treatment for advanced disease.

中文标题:SOHO?01：BAY 2927088在既往接受治疗但未接受过HER2靶向治疗或对晚期疾病尚未进行任何治疗的HER2突变NSCLC患者中的安全性与疗效研究

汇报者:Herbert H.Loong，MBBS，FRCP，FASCO|The Chinese University of Hong Kong

 

英文标题:Patritumab deruxtecan(HER3-DXd)in resistant EGFR-mutated(EGFRm)advanced non-small cell lung cancer(NSCLC)after a third-generation EGFR TKI:The phase 3 HERTHENA-Lung02 study.

中文标题:HERTHENA?Lung02Ⅲ期研究：Patritumab deruxtecan（HER3?DXd）用于对三代EGFR TKI耐药的EGFR突变晚期NSCLC患者

汇报者:莫树锦教授|香港中文大学

 

英文标题:Sacituzumab tirumotecan(sac-TMT)in patients(pts)with previously treated advanced EGFR-mutated non-small cell lung cancer(NSCLC):Results from the randomized OptiTROP-Lung03 study.

中文标题:OptiTROP?Lung03：芦康沙妥珠单抗在既往治疗过的EGFR突变晚期NSCLC患者中的应用——随机对照研究结果

汇报者:张力教授｜中山大学肿瘤防治中心

 

英文标题:Randomized phase II trial investigating whether atezolizumab after chemoradiotherapy(CRT)prolongs survival in limited stage(LS)small cell lung cancer(SCLC).

中文标题:局限期小细胞肺癌（SCLC）化放疗后使用阿替利珠单抗是否延长生存的随机Ⅱ期试验

汇报者:Bjorn Henning Gronberg，MD，PhD|Department of Clinical and Molecular Medicine，NTNU，Norwegian University of Science and Technology and Department of Oncology，St.Olavs Hospital

 

英文标题:Tarlatamab versus chemotherapy(CTx)as second-line(2L)treatment for small cell lung cancer(SCLC):Primary analysis of Ph3 DeLLphi-304.

中文标题:Tarlatamab对比化疗（CTx）二线（2L）治疗小细胞肺癌（SCLC）：3期DeLLphi-304研究主要分析

汇报者:Charles M Rudin，MD，PhD|Fiona and Stanley Druckenmiller Center for Lung Cancer Research，Memorial Sloan Kettering Cancer Center

 

英文标题:Phase I study of iza-bren(BL-B01D1)，an EGFR x HER3 bispecific antibody-drug conjugate(ADC)，in patients with locally advanced or metastatic small cell lung cancer(SCLC).

中文标题:iza-bren（BL-B01D1），一种EGFR x HER3双特异性抗体驱动药物偶联物（ADC），在局部晚期或转移性小细胞肺癌（SCLC）患者中的I期研究。

汇报者:黄岩教授|中山大学肿瘤防治中心

 

英文标题:Lurbinectedin(lurbi)+atezolizumab(atezo)as first-line(1L)maintenance treatment(tx)in patients(pts)with extensive-stage small cell lung cancer(ES-SCLC):Primary results of the phase 3 IMforte trial.

中文标题:IMforteⅢ期研究：芦比替定+阿替利珠单抗作为广泛期小细胞肺癌（ES?SCLC）患者一线维持治疗的主要结果

汇报者:Luis G.Paz-Ares，MD，PhD|Hospital Universitario 12 de Octubre，H12O-CNIO Lung Cancer Unit，Universidad Complutense and Ciberonc

 

英文标题:A phase 2 dose expansion study of ZG006，a trispecific T cell engager targeting CD3/DLL3/DLL3，as monotherapy in patients with advanced small cell lung cancer.

中文标题:ZG006治疗晚期小细胞肺癌的II期剂量扩展研究：靶向CD3/DLL3/DLL3的三特异性T接合器单药疗法评估

汇报者:艾星浩教授｜上海市胸科医院

 

 

英文标题:Perioperative nivolumab(NIVO)vs placebo(PBO)in patients(pts)with resectable NSCLC:Updated survival and biomarker analyses from CheckMate 77T.

中文标题:CheckMate 77T研究：可切除NSCLC患者围手术期纳武利尤单抗与安慰剂治疗对比的生存及生物标志物更新分析

汇报者:Mariano Provencio，MD，PhD|Hospital Universitario Puerta de Hierro

 

英文标题:SNF-CLIMEDIN:A HECOG prospective randomized trial of digital support and intervention in patients with advanced non-small cell lung cancer(NSCLC)—Final results.

中文标题:SNF-CLIMEDIN：HECOG对晚期非小细胞肺癌（NSCLC）患者数字支持和干预的前瞻性随机试验-最终结果。

汇报者:Paris A.Kosmidis，MD|Department of Medical Oncology，Hygeia Hospital

 

英文标题:Economic modelling to inform pricing for LMICs of immune checkpoint inhibitors in advanced PD-L1-high non-small cell lung cancer.

中文标题:为晚期PD-L1高表达非小细胞肺癌免疫检查点抑制剂LMICs定价提供经济模型

汇报者:Giulia Segafredo，PhD|Medicines Patent Pool

 

英文标题:Effect of broad-based genomic sequencing on survival outcomes in advanced non-small cell lung cancer:A national cohort study，2011-2023.

中文标题:广泛基因组测序对晚期非小细胞肺癌生存结果的影响：2011-2023年全国队列研究

汇报者:Patricia Mae Garcia Santos，MD，MS|Division of Health Services，Outcomes，and Policy，Department of Radiation Oncology，Winship Cancer Institute，Emory University

 

英文标题:Association of post-surgical MRD status with neoadjuvant ctDNA dynamics，genomic mutations，and clinical outcomes in patients with resectable NSCLC(R-NSCLC)from the phase 3 AEGEAN trial.

中文标题:AEGEAN III期研究：术后MRD状态与新辅助ctDNA动态、基因突变特征及可切除NSCLC患者预后的相关性分析

汇报者:Martin Reck，MD，PhD|Lung Clinic Grosshansdorf，Airway Research Center North，German Center for Lung Research

 

英文标题:ctDNA-based MRD detection in unresectable NSCLC undergoing curatively intended chemoradiotherapy and durvalumab.

中文标题:在接受根治性意图放化疗及度伐利尤单抗治疗的不可切除NSCLC患者中基于ctDNA的MRD检测研究

汇报者:Aslaug Helland，MD，PhD|University of Oslo，Clinical Medicine

 

英文标题:The preliminary results of a randomized phase II trial evaluating induction toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab in bulky unresectable stage III non-small-cell lung cancer(InTRist).

中文标题:InTRist研究：特瑞普利单抗联合化疗诱导治疗序贯同步放化疗+特瑞普利单抗巩固治疗用于不可切除、肿块型III期NSCLC的随机II期研究初步结果

汇报者:Yu Wang教授｜中国医学科学院北京协和医学院肿瘤医院

 

英文标题:Alectinib as neoadjuvant treatment in potentially resectable stage III ALK-positive NSCLC:Final analysis of ALNEO phase II trial(GOIRC-01-2020-ML42316).

中文标题:阿来替尼作为新辅助治疗用于潜在可切除III期ALK阳性NSCLC的ALNEO II期研究最终分析（GOIRC-01-2020-ML42316）

汇报者:Marcello Tiseo|Department of Medicine and Surgery，University of Parma;Medical Oncology Unit，University Hospital of Parma;Gruppo Oncologico Italiano di Ricerca Clinica，GOIRC

 

英文标题:Telisotuzumab adizutecan(ABBV-400;Temab-A)，a c-Met protein–targeting antibody-drug conjugate(ADC)，in patients(pts)with advanced EGFR-mutated(MT)non-squamous(NSQ)non-small cell lung cancer(NSCLC):Results from a phase 1 study.

中文标题:靶向c-Met的抗体偶联药物Telisotuzumab adizutecan（ABBV-400；Temab-A）治疗晚期EGFR突变型非鳞非小细胞肺癌（NSCLC）的Ⅰ期研究结果

汇报者:David Ross Camidge，MD，PhD|University of Colorado Cancer Center

 

英文标题:Efficacy and CNS results from a randomized subset of the phase 2 SAVANNAH study comparing savolitinib(savo)+osimertinib(osi)combination with savo+placebo(PBO).

中文标题:Ⅱ期SAVANNAH研究随机亚组结果：赛沃替尼联合奥希替尼vs.赛沃替尼联合安慰剂的疗效及中枢神经系统结果分析

汇报者:Benjamin Philip Levy，MD，FASCO|Sidney Kimmel Comprehensive Cancer Center，Johns Hopkins University School of Medicine

 

英文标题:Phase 3 study of benmelstobart in combination with chemotherapy followed by sequential combination with anlotinib for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer(sq-NSCLC).

中文标题:评估贝莫苏拜单抗联合化疗，序贯安罗替尼一线治疗局部晚期或转移性鳞状非小细胞肺癌（sq-NSCLC）的疗效的III期临床研究

汇报者:石远凯教授｜中国医学科学院肿瘤医院

 

英文标题:Plasma-guided adaptive first-line chemoimmunotherapy for non-small cell lung cancer(NSCLC).

中文标题:血浆引导的NSCLC一线个体化化免治疗探索

汇报者:Julia K.Rotow，MD|Lowe Center for Thoracic Oncology，Dana-Farber Cancer Institute

 

英文标题:Randomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non-small cell lung cancer.

中文标题:评估免疫化疗给药时间对非小细胞肺癌患者无进展生存期和总生存期影响的随机临床试验

汇报者:张永昌教授｜湖南省肿瘤医院

 

英文标题:Hypoxia-responsive CEA CAR-T cells therapy for relapsed or refractory non-small cell lung cancer:A single-arm，open-label，phase I trial.

中文标题:缺氧响应性CEA CAR-T细胞治疗复发或难治性非小细胞肺癌：一项单臂、开放标签的I期临床试验

汇报者:魏双教授｜华中科技大学同济医学院附属同济医院

 

英文标题:S1900E:A phase II study examining impact of co-mutations on sotorasib for previously treated stage IV/recurrent KRAS G12C mutated(MUT)non-squamous(Non-sq)non-small cell lung cancer(NSCLC)(ECOG-ACRIN led Lung-MAP Sub-study).

中文标题:S1900E研究：评估合并突变对索托拉西布治疗既往接受治疗的KRAS G12C突变IV期/复发性非鳞NSCLC疗效影响的II期研究（ECOG-ACRIN主导Lung-MAP子研究）

汇报者:Sukhmani Kaur Padda，MD|Fox Chase Cancer Center/Temple Health

 

英文标题:Safety and efficacy of olomorasib+immunotherapy in first-line treatment of patients with KRAS G12C-mutant advanced NSCLC:Update from the LOXO-RAS-20001 trial.

中文标题:Olomorasib联合免疫治疗用于KRAS G12C突变晚期NSCLC一线治疗的安全性和疗效：LOXO-RAS-20001研究更新

汇报者:Konstantin H.Dragnev，MD|Dartmouth Cancer Center

 

英文标题:Sosimerasib monotherapy in patients with previously treated KRAS G12C–mutated non-small cell lung cancer:Primary results of a phase 2 study.

中文标题:Sosimerasib单药治疗KRAS G12C突变非小细胞肺癌的II期研究主要结果

汇报者:王洁教授｜中国医学科学院肿瘤医院

 

英文标题:Association between wildfire-dominated PM2.5 exposure and non-small cell lung cancer survival in California.

中文标题:野外火灾主导的PM2.5暴露与加州非小细胞肺癌存活之间的关系

汇报者:Surbhi Singhal，MD|University of California Davis Comprehensive Cancer Center

 

英文标题:Perturbational single-cell RNA sequencing of patient tumors in Merkel cell and small cell lung carcinomas.

中文标题:Merkel细胞癌和小细胞肺癌患者肿瘤的扰动单细胞RNA测序研究

汇报者:Curtis J.Perry，MD，PhD|Yale School of Medicine

 

英文标题:Safety and efficacy of lurbinectedin plus atezolizumab as second-line treatment for advanced small-cell lung cancer:Results of the 2SMALL phase 1/2 study(NCT04253145).

中文标题:2SMALL1/2期研究：芦比替定联合阿替利珠单抗作为晚期小细胞肺癌二线治疗的安全性与疗效

汇报者:Santiago Ponce Aix，MD，PhD|Hospital Universitario 12 de Octubre and Oncosur Foundation

 

英文标题:Clinical and molecular characteristics of early progressors(EPs)and long-term progression-free survivors(LTPs)from the phase 3 ADRIATIC trial of consolidation durvalumab(D)vs placebo(P)after concurrent chemoradiotherapy(cCRT)in limited-stage small-cell lung cancer(LS-SCLC).

中文标题:ADRIATIC III期研究探索：同步放化疗后巩固度伐利尤单抗vs安慰剂用于LS-SCLC患者中早期进展者与长期无进展生存者的临床与分子特征

汇报者:David Allen Barbie，MD|Lowe Center for Thoracic Oncology，Dana-Farber Cancer Institute

 

英文标题:Efficacy and safety of nivolumab plus ipilimumab for patients with pre-treated type B3 thymoma and thymic carcinoma:Results from the EORTC-ETOP NIVOTHYM phase II trial.

中文标题:纳武利尤单抗联合伊匹木单抗治疗既往治疗的B3型胸腺瘤和胸腺癌患者的疗效与安全性：EORTC-ETOP NIVOTHYM II期研究结果II期研究结果

汇报者:Nicolas Girard，MD，PhD|Institut du Thorax Curie Montsouris，Institut Curie，Paris，and UVSQ，Paris Saclay University

 

英文标题:IntegrinαVβ3-targeted imaging for identification of lung cancer and mapping of lymph-node metastases:A prospective，multicenter，self-controlled phase 3 trial(TRIIL study).

中文标题:靶向整合素αVβ3显像在肺癌识别及淋巴结转移图谱绘制中的应用：TRIIL前瞻性、多中心、自身对照III期研究

汇报者:Rongxi Wang教授｜北京协和医院

 

 

英文标题:Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer:A bicentric bicontinental study.

中文标题:晚期非小细胞肺癌联合免疫化疗时间对总生存期的影响：双中心跨大陆研究。

汇报者:Francis Albert Lévi，MD，PhD|UPR Chronotherapie，Cancers et Transplantation，UniversitéParis Saclay，Hôpital Paul Brousse ID Isco 13918

英文标题:First-in-class PD-1/IL-2 bispecific antibody IBI363 in patients(Pts)with advanced immunotherapy-treated non-small cell lung cancer(NSCLC).

中文标题:IBI363（首创PD-1/IL-2双特异性抗体）治疗经免疫治疗后的晚期非小细胞肺癌患者

汇报者:周建娅教授｜浙江大学医学院附属第一医院

小细胞肺癌（SCLC）及其他胸部肿瘤

 

英文标题:Efficacy and safety of MHB088C，a novel B7-H3-targeted ADC，in patients with relapsed extensive-stage small cell lung cancer(ES-SCLC):Subgroup analysis from a phase 1/2 multicenter study.

中文标题:一项关于MHB088C（新型B7-H3靶向ADC）治疗复发广泛期小细胞肺癌的疗效与安全性的I/II期多中心研究的亚组分析

汇报者:沈琳教授｜北京大学肿瘤医院

 

英文标题:First report of efficacy and safety results from a phase 2 trial evaluating BNT327/PM8002 plus chemotherapy(chemo)as first-line treatment(1L)in unresectable malignant mesothelioma.

中文标题:BNT327/PM8002联合化疗一线治疗不可切除恶性间皮瘤的II期临床试验初步疗效与安全性结果的首次报告

汇报者:程颖教授｜吉林省肿瘤医院